Cybrids for Mitochondrial DNA Pharmacogenomics
Article first published online: 18 OCT 2012
© 2012 Wiley Periodicals, Inc.
Drug Development Research
Special Issue: Impact of Omics on Drug Discovery and Development. Part II
Volume 73, Issue 8, pages 453–460, December 2012
How to Cite
Iglesias, E., Llobet, L., Pacheu-Grau, D., Gómez-Durán, A. and Ruiz-Pesini, E. (2012), Cybrids for Mitochondrial DNA Pharmacogenomics. Drug Dev. Res., 73: 453–460. doi: 10.1002/ddr.21037
- Issue published online: 11 DEC 2012
- Article first published online: 18 OCT 2012
- Instituto de Salud Carlos III. Grant Numbers: FIS-PI08/0264, PI11/01301to ER-P
- cybrid cell lines
Several key components of the oxidative phosphorylation system are coded in mitochondrial DNA. In humans, the mutation rate of the mitochondrial genome is higher than that of nuclear DNA. Some of these mutations can modify the interaction of mitochondrial DNA-encoded products with different therapeutic drugs. Several of these mutations have survived evolution, therefore generating different mitochondrial DNA genetic backgrounds. Thus, personalized medicine approaches must consider these particular interactions. However, before incorporating this knowledge into patient treatments, cellular and molecular studies are required. In this review, we discuss the cybrid model as a tool for this type of analysis, along with the pitfalls and improvements that are necessary before the translation of such models to medical practice.